Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Recent Advances in Pancreatic Neoplasms: Part II
share announcement

Recent Advances in Pancreatic Neoplasms: Part II

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (20 September 2023) | Viewed by 5161

Special Issue Editors

Prof. Dr. Cosimo Sperti

E-Mail Website
Guest Editor
Department of Surgery, Oncology and Gastroenterology-DISCOG, University of Padua, Padua, Italy
Interests: chronic pancreatitis; cystic tumors; endocrine tumors; pancreatectomy; pancreatic neoplasms
Special Issues, Collections and Topics in MDPI journals
Dr. Domenico Bassi

E-Mail
Guest Editor
Department of Surgery, Oncology and Gastroenterology-DISCOG, University of Padua, Padua, Italy
Interests: chronic pancreatitis; cystic tumors; endocrine tumors; pancreatectomy; pancreatic neoplasms
Dr. Simone Serafini

E-Mail
Guest Editor
Department of Surgery, Oncology and Gastroenterology-DISCOG, University of Padua, Padua, Italy
Interests: chronic pancreatitis; cystic tumors; endocrine tumors; pancreatectomy; pancreatic neoplasms

Special Issue Information

Dear Colleagues,

It is my pleasure to invite you and members of your research group to submit an article for a Special Issue titled "Recent Advances in Pancreatic Neoplasms: Part II". This volume follows on from the previous one, in which more than 14 papers were published. For more details about the Special Issue, please visit: https://www.mdpi.com/journal/jcm/special_issues/Pancreatic_Neoplasms

Pancreatic cancer is the fourth leading cause of cancer death in Western countries, and will soon become the second leading cause of gastrointestinal cancer death. Surgery and adjuvant therapy remains the standard treatment, but the recurrence rate remains high. Multimodality treatment, that is, neoadjuvant therapy and a combination of chemotherapy, radiotherapy, immunotherapy, and surgery, appears to be essential to obtain better results, but definitive conclusions on its effectiveness are lacking. There is a need for an improved understanding of genetic alterations, clarification of the role of new biomarkers for precursor and invasive tumors, the identification of prognostic factors (i.e., nutritional, immunological, and surgical complications), and the management of recurrent cancer via tailored therapy. Furthermore, neuroendocrine tumors, including a variety of neoplasms with varying biological behaviors and treatments, are increasingly diagnosed in clinical practice. In particular, the management of small non-functioning tumors is still controversial, while the treatment of advanced disease requires novel research strategies. This Special Issue is focused on the latest developments and challenges in multimodality therapy for resectable and locally advanced pancreatic tumors, the search for prognostic factors for early and late outcomes after therapy, and the evaluation of novel strategies for individualized treatment. We invite relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics. 

Prof. Dr. Cosimo Sperti
Dr. Domenico Bassi
Dr. Simone Serafini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic cancer
  • familial pancreatic cancer
  • pancreatic neuroendocrine tumor
  • multimodality therapy
  • neoadjuvant therapy
  • nutrition and cancer
  • inflammation and cancer
  • surgical complications and survival
  • recurrent cancer
  • radiotherapy
  • immunotherapy

Related Special Issue

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

11 pages, 703 KiB  
Article
Pancreatic Neuroendocrine Neoplasms Larger than 4 cm: A Retrospective Observational Study of Surgery, Histology, and Outcome
by Anna Caterina Milanetto, Anna-Lea Gais Zürcher, Alina David, Matteo Fassan and Claudio Pasquali
J. Clin. Med. 2023, 12(5), 1840; https://doi.org/10.3390/jcm12051840 - 25 Feb 2023
Cited by 1 | Viewed by 1471
Abstract
Background: Pancreatic neuroendocrine neoplasms (pNENs) are often detected as large primary lesions, even with distant metastases, and their prognosis may be difficult to predict. Methods: In this retrospective study, we retrieved data of patients treated for a large pNEN in our Surgical Unit [...] Read more.
Background: Pancreatic neuroendocrine neoplasms (pNENs) are often detected as large primary lesions, even with distant metastases, and their prognosis may be difficult to predict. Methods: In this retrospective study, we retrieved data of patients treated for a large pNEN in our Surgical Unit (1979–2017) to evaluate the possible prognostic role of clinic-pathological features and surgery. Cox-proportional hazard regression models were used to find possible associations among some variables (clinical features, surgery, and histology) and survival at univariate and multivariate analyses. Results: Among 333 pNENs, we identified 64 patients (19%) with a lesion > 4 cm. Patients’ median age was 61 years, median tumor size was 6.0 cm, and 35 (55%) patients had distant metastases at diagnosis. There were 50 (78%) nonfunctioning pNENs, and 31 tumors localized in the body/tail region of the pancreas. Overall, 36 patients underwent a standard pancreatic resection (with 13 associated liver resection/ablation). Regarding histology, 67% of pNENs were N1, and 34% were grade 2. After a median follow-up of 48 months (up to 33 years), 42 patients died of disease. Median survival after surgery was 79 months, and six patients experienced recurrence (median DFS 94 months). At multivariate analysis, distant metastases were associated with a worse outcome, while having undergone radical tumor resection was a protective factor. Conclusions: In our experience, about 20% of pNENs have a size > 4 cm, 78% are nonfunctioning, and 55% show distant metastases at diagnosis. Nevertheless, a long-term survival of more than five years may be achieved after surgery. Full article
(This article belongs to the Special Issue Recent Advances in Pancreatic Neoplasms: Part II)
►▼ Show Figures

Figure 1

12 pages, 2443 KiB  
Article
Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience
by Lucia Moletta, Alberto Friziero, Simone Serafini, Valeria Grillo, Elisa Sefora Pierobon, Giovanni Capovilla, Michele Valmasoni and Cosimo Sperti
J. Clin. Med. 2023, 12(3), 1171; https://doi.org/10.3390/jcm12031171 - 01 Feb 2023
Cited by 3 | Viewed by 1076
Abstract
Pancreatic metastases from other neoplasms are rare. The role of surgery for this clinical entity is unclear. The aim of this study was to investigate the role of resection in patients with pancreatic secondary lesions. We observed 44 patients with pancreatic metastases from [...] Read more.
Pancreatic metastases from other neoplasms are rare. The role of surgery for this clinical entity is unclear. The aim of this study was to investigate the role of resection in patients with pancreatic secondary lesions. We observed 44 patients with pancreatic metastases from other tumors. Renal cell carcinoma was the most common primary tumor (n = 19, 43.2%). Thirty-seven patients underwent surgery, and pancreatic resection with curative intent was feasible in 35 cases. Fifteen patients (43.2%) experienced major postoperative complications (Clavien-Dindo > 2), and postoperative mortality rate was 5.4%. The median overall survival and disease-free survival were 38 (range 0–186) and 11 (range 0–186) months, respectively. Overall survival and disease-free survival were significantly longer for pancreatic metastases from renal cell carcinoma when compared to other primary tumors. Multivariate analysis confirmed a pathological diagnosis of metastasis from RCC as an independent prognostic factor for overall survival (OR 2.48; 95% CI, 1.00–6.14; p = 0.05). In conclusion, radical resection of metastases to the pancreas is feasible and safe, and may confer a survival benefit for selected patients. There is a clear benefit of metastasectomy in terms of patient survival for metastases from renal cell carcinoma, while for those with other primary tumors, surgery seems to be mainly palliative. Full article
(This article belongs to the Special Issue Recent Advances in Pancreatic Neoplasms: Part II)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

31 pages, 510 KiB  
Review
Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor
by Sergio Pedrazzoli
J. Clin. Med. 2023, 12(20), 6461; https://doi.org/10.3390/jcm12206461 - 11 Oct 2023
Cited by 2 | Viewed by 1018
Abstract
Background: Previously considered inoperable patients (borderline resectable, locally advanced, synchronous oligometastatic or metachronous pancreatic adenocarcinoma (PDAC)) are starting to become resectable thanks to advances in chemo/radiotherapy and the reduction in operative mortality. Methods: This narrative review presents a chosen literature selection, giving a [...] Read more.
Background: Previously considered inoperable patients (borderline resectable, locally advanced, synchronous oligometastatic or metachronous pancreatic adenocarcinoma (PDAC)) are starting to become resectable thanks to advances in chemo/radiotherapy and the reduction in operative mortality. Methods: This narrative review presents a chosen literature selection, giving a picture of the current state of treatment of these patients. Results: Neoadjuvant therapy (NAT) is generally recognized as the treatment of choice before surgery. However, despite the increased efficacy, the best pathological response is still limited to 10.9–27.9% of patients. There are still limited data on the selection of possible NAT responders and how to diagnose non-responders early. Multidetector computed tomography has high sensitivity and low specificity in evaluating resectability after NAT, limiting the resection rate of resectable patients. Ca 19-9 and Positron emission tomography are giving promising results. The prediction of early recurrence after a radical resection of synchronous or metachronous metastatic PDAC, thus identifying patients with poor prognosis and saving them from a resection of little benefit, is still ongoing, although some promising data are available. Conclusion: In conclusion, high-level evidence demonstrating the benefit of the surgical treatment of such patients is still lacking and should not be performed outside of high-volume centers with interdisciplinary teams of surgeons and oncologists. Full article
(This article belongs to the Special Issue Recent Advances in Pancreatic Neoplasms: Part II)

Other

Jump to: Research, Review

11 pages, 1141 KiB  
Systematic Review
The Importance of Reading the Skin: Cutaneous Metastases of Pancreatic Cancer, a Systematic Review
by Fortunato Cassalia, Anna Bolzon, Monica Ponzano, Laura Ventura, Andrea Danese, Paolo Del Fiore, Anna Belloni Fortina, Elio Jovine, Giampaolo Perri, Umberto Cillo and Giovanni Marchegiani
J. Clin. Med. 2024, 13(1), 104; https://doi.org/10.3390/jcm13010104 - 24 Dec 2023
Viewed by 1206
Abstract
Background: Pancreatic cancer is notorious for its aggressive nature and low survival rate, with less than 10% of patients surviving beyond five years. Early detection is difficult, but skin metastases can be a rare but significant indicator. This systematic review focuses on the [...] Read more.
Background: Pancreatic cancer is notorious for its aggressive nature and low survival rate, with less than 10% of patients surviving beyond five years. Early detection is difficult, but skin metastases can be a rare but significant indicator. This systematic review focuses on the epidemiology, clinical features, and histology of skin metastases from pancreatic cancer to determine their importance in early diagnosis and overall management of the disease. Materials and methods: Following PRISMA guidelines, we conducted an exhaustive search of MEDLINE/PubMed, EMBASE, and SCOPUS databases up to June 2023, using specific keywords. Four independent investigators screened the studies using predefined criteria, and two investigators checked the accuracy and consistency of the data extraction. We assessed the quality of the trials using adapted criteria from the Joanna Briggs Institute. A narrative synthesis rather than a meta-analysis was chosen because of the different study designs. Results: The final analysis included 57 patients with skin metastases from pancreatic cancer. Cutaneous metastases, although rare, presented with approximately equal gender distribution and a mean age of 63.4 years. Predominantly non-umbilical (77%), these metastases showed clinical diversity, ranging from asymptomatic nodules to painful or ulcerated lesions. Notably, skin metastases often preceded the diagnosis of primary pancreatic cancer (58%). Primary tumor characteristics revealed different localizations, with adenocarcinoma being the most prevalent histological type (77%). A significant association (p = 0.008) was observed between pancreatic tumor location and the timing of presentation of skin metastases. Tumors located in the body and tail of the pancreas were more likely to manifest skin metastases as an initial clinical manifestation (62.2%) than those in the head of the pancreas (20.8%). Conclusions: In conclusion, although skin metastases are rare, they are important indicators of pancreatic cancer, highlighting the need for multidisciplinary healthcare collaboration and thorough skin examination. Recognizing them could lead to earlier diagnosis, which is crucial in a cancer with limited treatment options. Full article
(This article belongs to the Special Issue Recent Advances in Pancreatic Neoplasms: Part II)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop